Jessica Rossi-Zucman

Jessica Rossi-Zucman

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 251 publications

Management of rare primary liver cancers: combined hepato-cholangiocarcinoma and fibrolamellar hepatocellular carcinoma.

Management of rare primary liver cancers: combined hepato-cholangiocarcinoma and fibrolamellar hepatocellular carcinoma.

Journal: JHEP reports : innovation in hepatology

Published: April 30, 2026

Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.

Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 24, 2026

HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.

HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 18, 2026

Clonal origin and early lineage divergence in adenosquamous carcinoma.

Clonal origin and early lineage divergence in adenosquamous carcinoma.

Journal: Cell reports

Published: January 20, 2026

Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis.

Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis.

Journal: Nature reviews. Gastroenterology & hepatology

Published: January 19, 2026

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.

Journal: medRxiv : the preprint server for health sciences

Published: December 03, 2025

Global Re-Analysis Confirms Absence of the DNAJB1::PRKACA Fusion in Hepatoblastoma. Comment on Fleifil et al. DNAJB1-PKAc Kinase Is Expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways. Cancers 2025, 17, 83.

Global Re-Analysis Confirms Absence of the DNAJB1::PRKACA Fusion in Hepatoblastoma. Comment on Fleifil et al. DNAJB1-PKAc Kinase Is Expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways. Cancers 2025, 17, 83.

Journal: Cancers

Published: November 12, 2025

Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative.

Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative.

Journal: Journal of hepatology

Published: October 17, 2025

Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French genomic medicine initiative.

Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French genomic medicine initiative.

Journal: Journal of hepatology

Published: October 17, 2025

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with early hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial).

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with early hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial).

Journal: Hepatology (Baltimore, Md.)

Published: October 16, 2025

Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma.

Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma.

Journal: Journal of hepatology

Published: October 15, 2025

Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.

Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.

Journal: Cancer research communications

Published: September 10, 2025

Showing 1-12 of 251

Last Updated: 09/26/2026